A new rescue regimen with plasma exchange and rituximab in high‐risk membranous glomerulonephritis
- 9 November 2015
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 45 (12) , 1260-1269
Abstract
Even though current treatment guidelines for idiopathic membranous glomerulonephritis (iMGN) exist, many questions regarding an optimal therapy remain unanswered. Complete remission cannot be achieved in all patients; relapses occur, in some cases frequently, and side effects from the immunosuppressive therapy are common. Therapeutic options in high-risk patients not responding to standard immunosuppressive therapies are limited. Recent research reveals that the human M-type phospholipase A2 receptor (PLA2R) is a causative factor in iMGN that parallels clinical disease activity. However, in some patients, this correlation is not evident and additional undetermined factors seem to play a role. We evaluated a new rescue protocol including plasma exchanges (PE) against albumin, intravenous immunoglobulins (IVIGs) and rituximab for 10 patients with a biopsy-proven diagnosis of iMGN who were therapy-resistant to all conventional regimens and had a urinary protein to creatinine ratio of more than 10 000 mg/g Crea. We compared this protocol with standard immunosuppressive protocols including monthly alternating prednisolone plus cyclophosphamide (18 patients), cyclosporine plus prednisolone (23 patients) and rituximab alone (eight patients) in a retrospective design. Our rescue regimen with PE, IVIGs and rituximab achieved partial remission in 90% of patients who had been otherwise refractory to therapy. The mean time to partial remission was 2·1 months. Furthermore, two anti-PLA2R-antibody negative patients were also treated with this rescue regimen, achieving partial remission after 1 and 4 months. A combination of PE, IVIGs and rituximab is a treatment option to consider for high-risk patients with iMGN who are refractory to conventional therapy.Keywords
This publication has 42 references indexed in Scilit:
- Rituximab for the second- and thirdline therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategyClinical Nephrology, 2013
- An Anti-Phospholipase A2 Receptor Quantitative Immunoassay and Epitope Analysis in Membranous Nephropathy Reveals Different Antigenic Domains of the ReceptorPLOS ONE, 2013
- Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous NephropathyJournal of the American Society of Nephrology, 2011
- Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2011
- Rituximab Therapy in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2010
- Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous NephropathyJournal of the American Society of Nephrology, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Autoimmunity in Membranous Nephropathy Targets Aldose Reductase and SOD2Journal of the American Society of Nephrology, 2010
- The changing pattern of adult primary glomerular diseaseNephrology Dialysis Transplantation, 2009
- A Randomized Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous NephropathyNew England Journal of Medicine, 1989